Contineum Therapeutics (CTNM) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Contineum Therapeutics is the larger company by market cap ($266.4 million vs $252.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | VCRE |
|---|---|---|
| Share price | $7.08 | $8.98 |
| Market cap | $266.36M | $252.92M |
| 1-day change | -10.38% | -1.21% |
| YTD return | -38.06% | — |
| 1-year return | -39.49% | — |
| EPS (TTM) | $-1.73 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-59.98M | — |
| 52-week high | $17.79 | $17.80 |
| 52-week low | $6.95 | $7.88 |
| Distance from 52-week high | -60.19% | -49.55% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +212.71% | +223.83% |
| Average volume | 732.62K | 17.84K |
| Shares outstanding | 32.96M | 28.16M |
| Employees | 51 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
CTNM vs VCRE FAQ
Which is bigger, Contineum Therapeutics or Vicore Pharma AB?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $266.36M compared with $252.92M for Vicore Pharma AB (VCRE).
Are Contineum Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.